7,571.69

+30.29

+0.40%

51,809.15

-174.83

-0.34%

25,375.56

+211.20

+0.84%

2,823.04

+17.16

+0.61%

4.9460

+0.0520

+1.06%

20.70

-0.45

-2.13%

3,934.10

-35.50

-0.89%

77,500.27

+548.80

+0.71%

Crude Oil Dec 26

96.13

-0.33

-0.34%

US Private Equity

10,836.30

-14.33

-0.13%

NasdaqCM - Nasdaq Real Time Price USD

Radiopharm Theranostics Limited (RADX)

0.8900 -0.1031 (-10.38%)

As of 1:59:54 PM EST. Market Open.

Loading Chart for RADX

Chart Range Bar

Interval:

In partnership with ChartIQ

Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics Reports Business Update

Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101

Radiopharm Completes Productive End-of-Phase 2 Meeting with U.S. Food and Drug Administration for Pivotal Development Program of RAD101

Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma

Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal Adenocarcinoma

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid Tumors

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical Trial

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

Radiopharm Theranostics To Meet with U.S. FDA to Align on Pivotal Phase 3 Trial Design for RAD 101 in Diagnosis of Brain Metastases

RADX: RAD101 Topline & FY:26 Cash Flows

RADX: RAD101 Topline & FY:26 Cash Flows

GE HealthCare Wins Approval for MINItrace Magni Cyclotron in Europe

GE HealthCare Wins Approval for MINItrace Magni Cyclotron in Europe

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting

Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual Meeting

Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics Reports Business Update

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan

Radiopharm Theranostics Announces Concurrent US$4.1 Million Registered Direct Offering and Up To Additional A$12.7 (US$8.9) Million Australian Placement and Share Purchase Plan

Mobilize your Website

View Site in Mobile | Classic

Share by: